Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on repurposing approved drugs, particularly itraconazole, for cancer treatment. It targets cancers such as basal cell carcinoma, prostate, and lung cancers by developing Hedgehog pathway inhibitors. The company advances clinical research, secures intellectual property, and seeks FDA designations to expedite approvals, aiming for market exclusivity and strategic partnerships in oncology therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.